ResMed has announced a deferral of conversions between its Australian and US share registers ahead of its quarterly dividend record date of 12 November 2026. The company will suspend processing of conversions, also known as transmutations, between its US common stock and Australian Chess Depositary Interests (CDIs) from 11 to 12 November, inclusive. This temporary suspension is designed to prevent duplicate or inconsistent dividend entitlements that could otherwise arise from the different settlement and transfer procedures governing the New York Stock Exchange and Australian Securities Exchange.
The core issue stems from ResMed’s dual listing on both major exchanges. Because the NYSE and ASX operate under different settlement protocols, the timing of cum-dividend and ex-dividend periods differs between the two registers. When conversions between registers occur during this timing mismatch, some security holders could receive duplicate dividend entitlements while others receive none. This creates operational and fairness issues that could undermine the integrity of the dividend distribution process.
To address this structural complexity, ResMed sought and received waivers from ASX Settlement Operating Rules 13.9.4 and 13.9.9, which typically mandate that conversions be processed continuously. The waivers provide the company with the legal authority to suspend conversion activity during the critical window around the record date. ResMed’s successful navigation of this regulatory process reflects strong governance and clear communication with both the ASX and NYSE regulators.
For investors holding ResMed shares on either register, this deferral creates a temporary constraint on converting between the two securities. Those with specific conversion needs around the dividend period should plan their transactions either before 11 November or after 12 November to avoid delays. The deferral is purely a technical measure affecting the mechanics of dividend administration and does not affect dividend eligibility or amounts.
The quarterly dividend itself remains on schedule, with the record date unchanged at 12 November and payment planned for 17 December 2026. Investors on both registers will receive their full dividend entitlements as announced. ResMed’s proactive approach to managing this dual-listed complexity protects all security holders from potential dividend complications that could arise from the different operational frameworks of the two exchanges.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARInvestors should monitor the company’s investor relations updates to confirm that conversions resume normally on 13 November and proceed throughout the remainder of the dividend cycle without further interruption. This announcement is price sensitive and has been flagged as material by the Australian Securities Exchange.
View the full ASX announcement (PDF)
About ResMed Inc (ASX: RMD)
ResMed Inc develops and manufactures medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders including sleep apnea, chronic obstructive pulmonary disease, and neuromuscular disease. The company supplies flow generators, masks, and accessories globally, with the majority of revenue derived from operations in the Americas. ResMed also pursues digital health initiatives and acquisitions to enhance clinical data offerings for patients, healthcare providers, and payers in out-of-hospital settings.
Become an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR